This inventor holds 1 USPTO granted patent. Top assignee: Locus Pharmaceuticals, Inc.. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Innovations of Stephan Brunner in Ligand-Residue Interaction Analysis
Introduction
Stephan Brunner is an accomplished inventor based in Preverenges, Switzerland. He has made significant contributions to the field of computational biology, particularly in the analysis of ligand-residue interactions. His innovative methods have the potential to enhance drug discovery processes.
Latest Patents
Stephan Brunner holds a patent for "Methods and systems for analyzing and determining ligand-residue interaction." This patent presents a method implemented in the form of a computer simulation code for evaluating the free energy of binding between polypeptide amino acid residues and one or more molecular fragment types. The method is based on a novel weighted Metropolis Monte Carlo approach for sampling the grand canonical ensemble. By utilizing the properties of the grand canonical ensemble, the affinity of fragments for binding near each protein residue can be efficiently computed. The binding volume associated with each fragment-residue pair is estimated using a simple proximity criterion, allowing for the generation of a useful affinity mapping of the protein surface. This analysis provides valuable insights for identifying protein binding sites and key fragments for potential drug leads.
Career Highlights
Stephan Brunner is currently associated with Locus Pharmaceuticals, Inc., where he continues to develop innovative solutions in the field of drug discovery. His work focuses on enhancing the understanding of molecular interactions, which is crucial for the development of new therapeutic agents.
Collaborations
Throughout his career, Stephan has collaborated with notable colleagues, including David Mosenkis and Frank Peter Hollinger. These collaborations have further enriched his research and contributed to advancements in the field.
Conclusion
Stephan Brunner's innovative work in ligand-residue interaction analysis exemplifies the intersection of computational methods and drug discovery. His contributions are paving the way for more effective therapeutic solutions in the pharmaceutical industry.